Overview

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

Status:
Completed
Trial end date:
2018-06-24
Target enrollment:
Participant gender:
Summary
This is an international, multicenter, randomized, double-blind, placebo-controlled, event driven study in subjects with pulmonary arterial hypertension.
Phase:
Phase 3
Details
Lead Sponsor:
United Therapeutics
Treatments:
Treprostinil